Clarify Complexity.
Streamline ADC Bioanalysis

 

From early development to PK studies, the Gyrolab® platform delivers low-volume, automated immunoassays that enhance precision, speed, and reproducibility. 

 

DOWNLOAD THE WHITE PAPER

Why antibody-drug conjugates (ADCs) demand more from bioanalysis

ADCs combine a monoclonal antibody, a potent payload, and a cleavable linker – making them one of oncology’s most promising yet complex modalities. Bioanalytical teams face challenges in characterising DAR, PK, and immunogenicity while managing matrix interference, sample scarcity, and regulatory rigour. Precise, reproducible data is essential across assays to ensure therapeutic efficacy.

With more than 15 ADCs now approved and hundreds more in clinical development, demand for scalable, reliable bioanalytical solutions has never been greater. 

The Gyrolab platform enables teams to keep pace with the growing complexity of ADC research supporting both innovation and compliance.

Antibody Drug Conjugate (ADC) components-3

Precision. Throughput. Confidence. Built In.

The Gyrolab platform provides nanoliter-scale, automated immunoassays designed to meet the high standards of ADC development, empowering scientists to deliver high-quality ADC data. It is ideal for biotech teams, CROs, and pharma innovators seeking automation-ready workflows that scale with clinical and regulatory demands. With faster turnaround times, lower sample volume, and superior reproducibility, it simplifies:

Free playload

DAR and PK quantification

joris

Total or conjugated antibody measurement

ADA result

ADA and biomarker analysis

lab2

Method development and validation for regulated environments

The rise of antibody-drug conjugates

Challenges and opportunities in development

Explore the drivers behind ADC innovation, the bottlenecks scientists encounter in the lab, and how new technologies are changing the game. This white paper offers an in-depth look at:

  • Analytical demands of next-gen ADCs
  • ADC assay development, matrix challenges, and DAR accuracy
  • Opportunities for automation and process efficiency
  • Industry trends across biotech, pharma, and CROs

Learn how the flexibility of the Gyrolab platform supports diverse ADC formats, including cleavable/non-cleavable linkers and cytotoxic payloads like MMAE, DM1, and Topo I inhibitors.

DOWNLOAD THE WHITE PAPER
Learn how the flexibility of the Gyrolab platform supports diverse ADC formats, including cleavable/non-cleavable linkers and cytotoxic payloads like MMAE, DM1, and Topo I inhibitors.

From DoE to decision in days

 

CASE STUDY: How Pfizer achieved GxP-quality ADC immunoassays with Gyrolab platform.

Discover how Pfizer streamlined their ADC assay development using the Gyrolab platform. By applying Design of Experiments (DoE) methodology, they rapidly developed and validated three ADC immunoassays — achieving:

Gyrolab xPand

orange bullet GxP-quality assay development in just 6 days

orange bullet 240 samples/day throughput

orange bullet Reproducibility with %CVs under 5%

orange bullet Assay precision and total error rivalling ELISA

orange bulletDramatically reduced reagent use and hands-on time

QC summary for TA assay​-1
DOWNLOAD THE CASE STUDY
logo-pfizer

“We were able to go from method development to GxP-ready assays in under a week — without compromising on accuracy or throughput.”

Senior Scientist, Pfizer Preclinical Bioanalysis

Advance with certainty. Deliver with confidence

Whether you’re developing in-house assays or outsourcing regulated studies, the Gyrolab platform helps ADC teams work faster, safer and smarter.

Learn how we support DAR, PK, and ADA assays with reproducible performance – even in complex matrices.

 


Cut processing time by up to 70% − Talk to an expert today